Table 1.
Human donor information for islet and acinar tissue preparations.
Table 2.
Human donor pancreas and spleen tissue from T2D and matched controls.
Table 3.
Human donor pancreas and spleen tissue from T1D and matched controls.
Fig 1.
Expression of hypusinated eIF5A (eIF5AHyp) in mouse and human pancreatic islets.
(A) Western blot from mouse and human pancreas tissue and isolated pancreatic islets. (B) Western blot from FACS sorted mouse islet cell populations. (C, D) Representative immunofluorescence images of mouse tissue demonstrating robust expression of eIF5AHyp in PP-expressing cells.
Fig 2.
The expression pattern of eIF5AHyp in T2D and control pancreatic tissue.
In controls (matched for age, gender and BMI) and T2D pancreas, we evaluated the co-expression of eIF5AHyp with all islet hormones and found no overlap with insulin (A,B), glucagon (C,D), ghrelin (E,F) or somatostatin (G,H).
Fig 3.
eIF5AHyp is robustly expressed in the pancreatic polypeptide-expressing PP cells in the islet.
(A-D) In both controls and T2D pancreas, co-expression of eIF5AHyp with pancreatic polypeptide (PP) and chromograninA (ChgA) was observed. (E) An expression pattern of eIF5AHyp in the PP cells suggestive of localization to the ER was observed in cells in both controls and T2D pancreas.
Fig 4.
eIF5AHyp expression pattern in the spleen of control and T2D.
eIF5AHyp is expressed in immune cells in the spleen. We evaluated expression of eIF5AHyp in Pax5+ B cells, CD4+ T cells and CD8+ T cells in the spleens of donors with T2D and controls matched for age, gender and BMI. Most eIF5AHyp+ cells co-expressed Pax5+ (A,D); however, a select group of eIF5AHyp+ cells expressed either CD4+ (B,E) or CD8+ (C,F).
Fig 5.
Expression of eIF5AHyp in the T1D pancreas.
(A-F) Identical to the pattern identified in T2D and control tissues, high expression of eIF5AHyp is observed in PP cells in the T1D, both auto-antibody positive (aAb+) and auto-antibody negative(aAb-), pancreas and controls (matched for age, gender, ethnicity and BMI). (G-I) In all cases, these cells express the endocrine cell marker ChromograninA (ChgA).
Fig 6.
Expression of eIF5AHyp in spleen tissue from donors with T1D and matched control donors.
We examined spleen tissue from persons with autoantibody positive (AAb+) and auto-antibody negative (AAb-) T1D, and corresponding controls matched for age, gender, ethnicity, and BMI. As observed in T2D and matched control spleen tissue, most eIF5AHyp-expressing cells were Pax5+ (A-C); however, some eIF5AHyp+ cells expressed either CD4+ (D-F) or CD8+ (G-I).